AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16627459 — intervention group
Group type: COMPARATOR
Intervention: Burst+ ATP therapy
Number of subjects: 176
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: Major clinical events
Number of subjects: 176
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication toxicity
Number of subjects: 176
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms
Number of subjects: 176
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: AF burden
Number of subjects: 176
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life
Number of subjects: 176
Study 14670764 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children with obstructive sleep related disordered breathing (SDB)
Number of subjects: 46
Study 14670764 — intervention group
Group type: COMPARATOR
Intervention: Normal weight children
Number of subjects: 46
Study 14670764 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pharyngeal lymphoid tissue in obese children
Number of subjects: 46
Study 10962588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bug Busting method (mechanical removal by wet combing)
Number of subjects: 0
Study 10962588 — intervention group
Group type: COMPARATOR
Intervention: Single application insecticide product
Number of subjects: 0
Study 7633976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant as a topical haemostatic agent
Number of subjects: 17
Study 7633976 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 17
Study 2677123 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for C. pylori gastritis and NUD
Number of subjects: 14
Study 2677123 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study 309095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prednisone (29 mg/day) and cyclophosphamide (107 mg/day) for six months
Number of subjects: 50
Study 309095 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg/day) for six months
Number of subjects: 50
Study 30921466 — intervention group
Group type: EXPERIMENTAL
Intervention: Random modulation
Number of subjects: 39
Study 30921466 — intervention group
Group type: EXPERIMENTAL
Intervention: No modulation
Number of subjects: 39
Study 30921466 — intervention group
Group type: EXPERIMENTAL
Intervention: 6s-6s modulation
Number of subjects: 39
Study 30921466 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 39
Study 30921466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed frequency
Number of subjects: 39
Study 28822253 — intervention group
Group type: EXPERIMENTAL
Intervention: New Orleans Intervention Model (NIM)
Number of subjects: 63
Study 28822253 — intervention group
Group type: COMPARATOR
Intervention: Social work 'services as usual'
Number of subjects: 63
Study 26154338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Telehealth (HT) system
Number of subjects: 302
Study 26154338 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 302
Study 23123915 — intervention group
Group type: EXPERIMENTAL
Intervention: Local laboratory measurements
Number of subjects: 0
Study 23123915 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory measurements
Number of subjects: 0
Study 21550959 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 75/25
Number of subjects: 0
Study 21550959 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 21550959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin/thiazolidinedione
Number of subjects: 0
Study 21550959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin/sulfonylurea/thiazolidinedione
Number of subjects: 0
Study 18499631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulation (group NS)
Number of subjects: 80
Study 18499631 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guidance (group US)
Number of subjects: 80
Study 16541243 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 102
Study 16541243 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg caffeine
Number of subjects: 102
Study 16541243 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg caffeine
Number of subjects: 102
Study 16541243 — intervention group
Group type: COMPARATOR
Intervention: 0 mg caffeine (control)
Number of subjects: 102
Study 16541243 — intervention group
Group type: EXPERIMENTAL
Intervention: All caffeine doses (50, 150, 450 mg)
Number of subjects: 102
Study 12704403 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 696
Study 12704403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 10741634 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 12
Study 10741634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9283061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff size 13 x 23 cm
Number of subjects: 130
Study 9283061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff size 13 x 36 cm
Number of subjects: 130
Study 9283061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff size 16 x 23 cm
Number of subjects: 130
Study 8396784 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiradoline (0.0, 0.8, 1.6, and 3.2 micrograms/kg)
Number of subjects: 5
Study 8396784 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiradoline (1.6 micrograms/kg)
Number of subjects: 5
Study 8396784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3793549 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 of doxorubicin every 3 weeks for eight courses
Number of subjects: 225
Study 3793549 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (optional)
Number of subjects: 225
Study 3793549 — intervention group
Group type: COMPARATOR
Intervention: No radiation therapy
Number of subjects: 225
Study 29684633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan gel
Number of subjects: 280
Study 29684633 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 280
Study 29373432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 15
Study 29373432 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 15
Study 29373432 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT and ET
Number of subjects: 15
Study 26522923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation plus hyperproteic oral nutritional supplement enriched with HMB (PRONS)
Number of subjects: 30
Study 26522923 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 30
Study 26522923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PR and PRONS)
Number of subjects: 30
Study 24439972 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Pill (initially strength 1-telmisartan 20 mg, amlodipine 2.5 mg, hydrochlorothiazide 6.25 mg, with the option of subsequent titration to strength 2-telmisartan 40 mg, amlodipine 5 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 700
Study 24439972 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 22839453 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 12
Study 22839453 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 12
Study 20212299 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP assistance
Number of subjects: 258
Study 20212299 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 258
Study 18558915 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping the blues away (KBA) program
Number of subjects: 110
Study 18558915 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 110
Study 15999098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose rate gemcitabine
Number of subjects: 76
Study 12453952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glipizide (30 min premeal)
Number of subjects: 20
Study 12453952 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg nateglinide (15 min premeal)
Number of subjects: 20
Study 12453952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glipizide plus 120 mg nateglinide (30 and 15 min premeal, respectively)
Number of subjects: 20
Study 12453952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 and 15 min premeal)
Number of subjects: 20
Study 12453952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 20
Study 12453952 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 20
Study 12453952 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide and Nateglinide
Number of subjects: 20
Study 10353432 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg
Number of subjects: 15
Study 10353432 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 15
Study 10353432 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 15
Study 10353432 — intervention group
Group type: COMPARATOR
Intervention: Desipramine 100 mg
Number of subjects: 15
Study 10353432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8942420 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared meal plan
Number of subjects: 77
Study 8942420 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet
Number of subjects: 77
Study 9768208 — intervention group
Group type: EXPERIMENTAL
Intervention: Heberbiovac HB vaccine
Number of subjects: 106
Study 9768208 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B vaccine (control)
Number of subjects: 106
Study 6383225 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 100
Study 6383225 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 30666097 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting Centres Support Programme (MCSP)
Number of subjects: 47
Study 30666097 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 47
Study 30080248 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care management for PPROM
Number of subjects: 187
Study 30080248 — intervention group
Group type: EXPERIMENTAL
Intervention: PPROM occurring before 26 weeks
Number of subjects: 187
Study 30080248 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cephalic fetal presentation
Number of subjects: 187
Study 30080248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligoamnios
Number of subjects: 187
Study 30080248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of unfavorable criteria
Number of subjects: 187
Study 27084855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 1 gm, 1 hour preoperatively and 2 gm for 2 days postoperatively (Test group)
Number of subjects: 40
Study 27084855 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Control group)
Number of subjects: 40
Study 24799054 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab (4 mg/kg), gemcitabine (1000 mg/m(2)), docetaxel (50 mg/m(2))
Number of subjects: 65
Study 23210420 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F mouthwash
Number of subjects: 30
Study 23210420 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 ppm F mouthwash
Number of subjects: 30
Study 23210420 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm F mouthwash
Number of subjects: 30
Study 20451214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-band spatial frequency bias in adults and 9- and 10-year-olds for upright faces
Number of subjects: 2
Study 20451214 — intervention group
Group type: COMPARATOR
Intervention: Processing of upright and inverted faces in 7- and 8-year-olds
Number of subjects: 2
Study 18758336 — intervention group
Group type: EXPERIMENTAL
Intervention: Class that used video demonstration and group teaching by a lactation consultant
Number of subjects: 194
Study 18758336 — intervention group
Group type: EXPERIMENTAL
Intervention: New mothers' support group with one-on-one teaching prenatally and weekly meetings postpartum, taught by a lactation consultant and a pediatrician
Number of subjects: 194
Study 18758336 — intervention group
Group type: COMPARATOR
Intervention: Control group educated at prenatal visits only
Number of subjects: 194
Study 15768008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Quality of Life (VascuQol)
Number of subjects: 450
Study 15768008 — intervention group
Group type: COMPARATOR
Intervention: Short Form 36 (SF‐36)
Number of subjects: 450
Study 15768008 — intervention group
Group type: COMPARATOR
Intervention: European Quality of Life 5D (EuroQol‐5D)
Number of subjects: 450
Study 11788218 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2431
Study 11788218 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 2431
Study 11788218 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed registry (CABG)
Number of subjects: 2431
Study 11788218 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-directed registry (PCI)
Number of subjects: 2431
Study 11788218 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-choice registry (PCI)
Number of subjects: 2431
Study 11788218 — intervention group
Group type: COMPARATOR
Intervention: Patient-choice registry (CABG)
Number of subjects: 2431
Study 10627057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy evening meal (11.91 +/‐ 0.86 MJ)
Number of subjects: 7
Study 10627057 — intervention group
Group type: EXPERIMENTAL
Intervention: Average evening meal (5.74 +/‐ 0.88 MJ)
Number of subjects: 7
Study 10627057 — intervention group
Group type: COMPARATOR
Intervention: 10-hour fast (no evening meal)
Number of subjects: 7
Study 10627057 — intervention group
Group type: EXPERIMENTAL
Intervention: All meal conditions (high-energy, average, and fast)
Number of subjects: 7
Study 7806146 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms subcutaneously)
Number of subjects: 30
Study 7806146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2009800 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 38
Study 2009800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7384524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg)
Number of subjects: 30
Study 7384524 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 30849076 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 15
Study 30849076 — intervention group
Group type: COMPARATOR
Intervention: Open-loop insulin delivery
Number of subjects: 15
Study 26096071 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 51
Study 26096071 — intervention group
Group type: COMPARATOR
Intervention: Posterior Approach (PA)
Number of subjects: 51
Study 25685075 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention
Number of subjects: 40
Study 22814329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex (ABLC) 7.5 mg/kg weekly
Number of subjects: 40
Study 22814329 — intervention group
Group type: COMPARATOR
Intervention: Oral posaconazole 200 mg three times per day
Number of subjects: 40
Study 20061280 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized order set (CPOE)
Number of subjects: 179
Study 20061280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 179
Study 17983400 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of cytoxan, adriamycin and 5‐flurouricil (5‐FU)
Number of subjects: 464
Study 17983400 — intervention group
Group type: COMPARATOR
Intervention: 16‐week regimen (weekly therapy with cytoxan, adriamycin, vincristine, methotrexate, and 5‐FU)
Number of subjects: 464
Study 17983400 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQOL score as a time‐dependent covariate
Number of subjects: 464
Study 17983400 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 464
Study 17983400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea
Number of subjects: 464
Study 17983400 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosensory toxicity
Number of subjects: 464
Study 17983400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair loss
Number of subjects: 464
Study 15727949 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) alone
Number of subjects: 12
Study 15727949 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) plus Testosterone (T)
Number of subjects: 12
Study 15727949 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T) alone
Number of subjects: 12
Study 15727949 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) plus Growth Hormone (GH)
Number of subjects: 12
Study 15727949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (GH and T)
Number of subjects: 12
Study 12402373 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml saline instillation
Number of subjects: 16
Study 12402373 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml saline instillation
Number of subjects: 16
Study 12402373 — intervention group
Group type: COMPARATOR
Intervention: 0 ml saline instillation (no saline)
Number of subjects: 16
Study 9931783 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal retroperitoneoscopic adrenal gland resection
Number of subjects: 24
Study 9931783 — intervention group
Group type: COMPARATOR
Intervention: Complete adrenalectomy
Number of subjects: 24
Study 8074058 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted meal (2671 kJ/L, 950 mL)
Number of subjects: 9
Study 8074058 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated meal (7452 kJ/L, 350 mL)
Number of subjects: 9
Study 8074058 — intervention group
Group type: COMPARATOR
Intervention: Both meals (diluted and concentrated)
Number of subjects: 9
Study 2524360 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 0
Study 2524360 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon 30
Number of subjects: 0
Study 2524360 — intervention group
Group type: EXPERIMENTAL
Intervention: Triquilar
Number of subjects: 0
Study 30541475 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint (PEP)
Number of subjects: 71
Study 30541475 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoint (SEP)
Number of subjects: 71
Study 30541475 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SEPs absent from registry and protocol
Number of subjects: 71
Study 27582078 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Sunitinib (SUN)
Number of subjects: 91
Study 27582078 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI + Placebo (PL)
Number of subjects: 91
Study 25641731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg)
Number of subjects: 47
Study 25641731 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg)
Number of subjects: 47
Study 25641731 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous dosage of ascorbic acid and aspirin
Number of subjects: 47
Study 25641731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 23732903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine RV5 (RotaTeq™), 3-dose regimen
Number of subjects: 0
Study 20007736 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PROP)
Number of subjects: 25
Study 20007736 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 25
Study 19025033 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive training with identical stimuli
Number of subjects: 12
Study 19025033 — intervention group
Group type: COMPARATOR
Intervention: Fixed training with identical stimuli
Number of subjects: 12
Study 16882163 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar (n = 13)
Number of subjects: 30
Study 16882163 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐trans retinoic acid (atRA) (n = 14)
Number of subjects: 30
Study 16882163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol 17‐propionate (n = 10)
Number of subjects: 30
Study 16882163 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (white soft paraffin)
Number of subjects: 30
Study 12928710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(1) injection before CTAP
Number of subjects: 30
Study 12928710 — intervention group
Group type: COMPARATOR
Intervention: No prostaglandin E(1) injection (group A)
Number of subjects: 30
Study 11211541 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly structured interventions for six months (Group 1, n = 42)
Number of subjects: 80
Study 11211541 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2, n = 38)
Number of subjects: 80
Study 8801153 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 81
Study 8801153 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 81
Study 1519364 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions (predeposition of 2 units)
Number of subjects: 310
Study 1519364 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusions (control)
Number of subjects: 310
Study 1519364 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions
Number of subjects: 310
Study 6829481 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fats (sat)
Number of subjects: 12
Study 6829481 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fats (mono)
Number of subjects: 12
Study 6829481 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-6 polyunsaturated fats (poly)
Number of subjects: 12
Study 6829481 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-free formula diet
Number of subjects: 12
Study 30696677 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-screw group
Number of subjects: 70